| RETROPERITONEAL
LYMPHADENECTOMY BY VIDEOLAPAROSCOPIC TRANSPERITONEAL APPROACH IN PATIENTS
WITH NON-SEMINOMATOUS TESTICULAR TUMOR
(
Download pdf )
M. TOBIAS-MACHADO,
JOÃO P. ZAMBON, ALEXANDRE D. FERREIRA, JIMMY A. MEDINA, ROBERTO
V. JULIANO, ERIC R. WROCLAWSKI
Discipline
of Urology, ABC Medicine School, Santo André, São Paulo,
Brazil
ABSTRACT
Objective:
The present study aims to report the preliminary experience with videolaparoscopic
retroperitoneal lymphadenectomy in the treatment of patients with non-seminomatous
testicular tumor.
Materials and Methods: Seven surgeries were
performed in order to access retroperitoneal lymph nodes in patients with
non-seminomatous testicular cancer. We performed the videolaparoscopic
retroperitoneal lymphadenectomy (LRL) technique in 5 patients with stage
I disease and laparoscopic resection of residual mass (LRRM), following
chemotherapy (ChT), in 2 patients with stage II disease. Initial approach
was obtained through 4 trocars, using an incision in supra-umbilical midline
when manual assistance was required. Surgical time was analyzed, as well
as blood loss, need for analgesic drugs postoperatively, hospital stay,
complications, need for blood transfusion, histopathological data and
tumor control in a mean follow-up of 18 months.
Results: Mean surgical time was 200 to 260
minutes in LRL and LRRM groups respectively, mean blood loss was 300 mL
for the LRL group and 400 mL for the LRRM group, without need for transfusions.
There was a lesion in the vena cava in the LRL group, which was managed
with manual assistance and one conversion in the LRRM group, due to a
10-cm tumor mass that was adhered to the aorta. Mean hospital stay was
3 days, excluding the converted case, and the use of analgesic drugs was
needed until the second postoperative day. Of the stage I patients, 2
had active disease in retroperitoneum, and underwent adjuvant ChT. The
2 residual masses were teratomas. There was no recurrence during the follow-up
period.
Conclusions: Videolaparoscopic retroperitoneal
lymphadenectomy is a procedure with high technical complexity and a higher
potential for conversion when performed following chemotherapy.
Key
words: testis; testicular neoplasms; germ cell tumors; chemotherapy;
lymphadenectomy; laparoscopy
Int Braz J Urol. 2004; 30: 389-97
INTRODUCTION
Conventional
retroperitoneal lymphadenectomy is a major surgical procedure, which confers
considerable morbidity to patients with non-seminomatous testicular tumor.
In patients with advanced disease who are already debilitated by the effects
of chemotherapy, the surgical procedure will bring an additional morbidity,
impairing their quality of life (1).
The retroperitoneal lymphadenectomy is indicated
mainly for staging of stage I non-seminomatous tumors, and the resection
of residual masses following chemotherapy (ChT) (1). The laparoscopic
surgery has lower morbidity when compared with open surgery and some studies
show that there is no impairment in the oncologic control of the disease
(2-12).
Pathological staging of retroperitoneal
lymph nodes in patients with non-seminomatous tumors offers 2 advantages:
patients with metastatic disease can be identified and treated, and those
without metastatic disease can be closely observed (1,11,12).
In patients with metastatic testicular tumors
who undergo previous ChT, there is formation of cicatricial tissue that
adheres to the great vessels, which can make tumor resection difficult
following ChT (5,8). The usual chemotherapy scheme using cisplatin as
basic drug provides 60 to 70% of satisfactory results, while approximately
30% of patients should undergo a surgical procedure (11,12). In such cases,
it is recommended that the laparoscopic surgery as a minimally invasive
procedure should be performed with caution, due to the risk of vascular
damage with consequent conversion to open surgery, increasing postoperative
morbidity (5,7,8,10-12).
In Brazil, the use of the laparoscopic approach
has been performed in a few centers, due to the rarity of the disease
and the technical complexity of the procedure (8). The objective of this
work was to report the preliminary experience with videolaparoscopic retroperitoneal
lymphadenectomy in the treatment of patients with non-seminomatous testicular
tumor.
MATERIALS
AND METHODS
Selection
Criteria
In the period from January 1999 to December
2002, we retrospectively studied 7 patients diagnosed with non-seminomatous
testicular cancer who underwent laparoscopic retroperitoneal lymphadenectomy
(Table-1). Patients did not present any contra-indication for surgery
and were in good general conditions, with American Society of Anesthesiologists
(ASA) score I and II. All patients were operated in a reference teaching
institution in Brazil, by the same surgeon.
Laparoscopic retroperitoneal lymphadenectomy
was performed in the following situations: 1) – Staging for stage
I non-seminomatous testicular cancer presenting risks factors such as
vascular invasion, invasion of spermatic cord or predominance of embryonal
carcinoma in neoplasic components. 2) – Post-chemotherapy resection
of residual masses smaller than 6 cm as measured by tomography.
The procedure was always initiated by laparoscopic
transperitoneal approach. The hand-assisted technique was used as an alternative
to avoid conversion to exclusive open surgery in those patients who presented
intraoperative complications or in cases where postchemotherapy fibrosis
prevented the safe dissection of the great vessels, (13).
Preoperative staging was performed using
thorax and abdomen computerized tomography (CT) and tumor markers (alpha-fetoprotein,
beta-subunit of human chorionic gonadotropin and lactic dehydrogenase).
The employed chemotherapy scheme, if indicated, was 4 PEB cycles (cisplatin,
etoposide and bleomycin).
Medical records were assessed in order to
observe technical aspects, postoperative complication, conversion rate
and postoperative outcome in relation to tumor control. The clinical follow-up
of patients ranged from 10 to 28 months.
Five patients had their surgeries indicated
for tumoral staging, with 3 cases due to the presence of a predominant
embryonal component and 2 due to vascular invasion.
Among these, 3 patients had tumor in the
right testis and 2 in the left one. Two patients underwent postchemotherapy
resection of residual retroperitoneal mass.
Transperitoneal
Laparoscopic Retroperitoneal Lymphadenectomy
Surgical
Technique
1 - Preoperative: Patients were admitted
to hospital one day prior to surgery and underwent 8-hour fasting and
reservation of red cells concentrate. All underwent general anesthesia
with vesical catheter, nasogastric tube and antibiotic coverage during
anesthetic induction with first generation cephalosporin. Ureteral catheterization,
to facilitate intraoperative identification of ureters, was not performed
in any case.
2 - Positioning and installation of trocars:
After positioning the patient in lateral decubitus at 60 degrees, 4 trocars
were placed: one 10-mm trocar in the umbilical scar, for introducing the
0-degree optics, two 5-mm trocars, one in the midline between the umbilical
scar and the xiphoid process and the other in the midline between the
pubis and the umbilical scar. This set-up allows the port incisions to
be united inside the surgical incision, in case of conversion to open
surgery. A 10-mm trocar was placed 2 cm below the umbilical scar at the
lateral margin of the rectus muscle of abdomen on the side to be approached
(Figure-1).
3 - Dissection technique: The dissection
limits were the same as in open surgery (7). Access to the retroperitoneal
space was achieved by an incision in the Toldt line, anterior and medially
displacing the colon. For the 5 patients with stage I tumor, the modified
lymphadenectomy was performed with interaortocaval dissection. For right-sided
testicular tumors, the upper dissection limits were the renal hilum bilaterally,
including the ureter at the left and extending downwards until the inferior
mesenteric artery. At this point, the dissection was directed to the right
side, following the right aortic margin and the right common iliac artery
until the crossing point of the ureter. Posterior dissection limit corresponded
to the anterior spinous ligament. For tumors located in the left testis,
the dissection was similar to the previous one, being more economic for
the contralateral side, where the inferior limit was the inferior vena
cava and not the ureter.
Ultrasonic or bipolar scalpel was used for
resecting the lymphatic tissue and the surgical specimen was removed through
entrapment in plastic packaging.
Hand-Assisted
Retroperitoneal Lymphadenectomy
Surgical
Technique
This technique was performed through a midline
supra-umbilical incision located above the renal hilum or close to the
lesion, without using manual device, including whenever possible the location
of one of the previously described ports (Figures-2 and 3).
In the 2 patients with post-ChT residual
mass, total resection of the mass was performed.
RESULTS
In
the group of patients with surgical indication for staging, mean age was
25 years and mean body mass index was 23 kg/m2. Mean surgical time was
200 minutes (160 - 360) and mean blood loss was 300 mL, with no need for
transfusion.
There was one intra-operative complication
with damage to the inferior vena cava, which was resolved by vascular
control, using hand-assisted access, with a 7-mm supra-umbilical midline
incision, including the supra-umbilical port, without a device for pneumoperitoneum
contention. After digital compression of the vena cava, it was possible
to place 2 Doyan valves, applying a Satinski clamp and closing the lesion
with 5-0 Prolene suture, externally, with no additional enlargement of
the incision. In this case there was no impairment in relation to the
laparoscopic access, since, once the vascular suture was completed, we
were able to conclude the procedure through hand-assisted laparoscopic
approach. Thus, we did not consider this temporary transition between
open and laparoscopic techniques as a conversion to definitive open approach.
There was no conversion to definitive open surgery in this group.
In the LRRM group, mean age was 27 years
and mean body mass index was 21 kg/m2. Mean surgical time was 260 minutes
(240-280) and mean blood loss was 400 mL, and blood transfusions were
not required. There was no intraoperative complication, and in one case,
we needed to perform a conversion to open surgery due to an extensive
tumor, larger than 10 cm, located in para- and retro-aortic regions. Preoperative
tomography performed 45 days before the surgery revealed a 6-cm residual
mass, and for this reason, the patient was included in the study (Table-2).
Data relative to postoperative outcome can
be observed in Table-3.
No postoperative complication was observed
during the follow-up, in the 2 groups of patients.
Of the 5 stage I patients, 2 presented positive
lymph nodes for non-seminomatous tumor and subsequently underwent adjuvant
chemotherapy. In the 2 patients undergoing post-ChT resection of residual
mass (Figure-4) the pathological report revealed that it was a teratoma,
with no need for complementary treatment.
There was no case of local or systemic recurrence
during a mean follow-up of 18 months in both groups under study. Postoperative
follow-up revealed that all patients maintained normal anterograde ejaculation.
COMMENTS
There
is much discussion regarding the best approach to stage I non-seminomatous
testicular tumors. While some authors advocate a careful follow-up, based
on the efficacy of the chemotherapic drugs used for treating this disease
(12), others prefer the retroperitoneal lymphadenectomy with diagnostic
and therapeutic purposes. The main argument for this management is the
fact that microscopic metastases can be present in approximately 30% of
cases (12-16), with 70% being free from disease without requiring cytotoxic
chemotherapy.
Another indication for lymphadenectomy is
related to the assessment of post-ChT response in patients with residual
tumors in advanced stage. With the availability of effective second-line
chemotherapic agents, a proper diagnosis can be fundamental for an accurate
indication of rescue ChT in cases with an active malignant component (8-10,12,14-18).
The incidence of retroperitoneal teratoma
ranges from 8 to 13% (1,8). These tumors have a proven malignant potential,
grow rapidly, and can invade adjacent structures with consequent functional
impairment to the patient. Moreover, these tumors are resistant to radio
and chemotherapy (1,9). Considering this evidence, some authors advocate
the performance of retroperitoneal lymphadenectomy even in patients with
negative radiological findings (5,9,18). In cases with retroperitoneal
mass larger than 1.5 cm or primary tumors up to 5 cm, regardless the response
to ChT, since they present negative tumoral markers, lymphadenectomy has
a precise indication (5,8-10,12). In the present study, the 2 post-ChT
residual masses were teratomas and the surgery certainly benefited the
patients (2,3,10,12).
Especially in laparoscopic access, where
there is greater technical difficulty for lymphatic resection posterior
to the great vessels, it is currently recommended to perform the modified
unilateral resection or isolated resection of the post-ChT residual mass.
This proposal is based on the distribution of retroperitoneal metastases
for non-seminomatous tumors proposed by Wood et al. (11). According to
these authors, the lymphatic drainage on the right side is directed to
the lymph nodes located in the interaortocaval space, and to the left
para-aortic and pre-aortic lymph nodes on the left side. In patients who
underwent previous ChT, the sites of metastatic spread are similar to
the sites of primary tumor and approximately 8% of the tumors would be
outside the resection area (11,12). Previously described data suggest
that there is no benefit in routine retroaortic and retrocava lymphadenectomy.
In this study, we performed retrocava dissection only in our first patient
(case with longer surgical time). Routinely, we adopted the interaortocaval
dissection regardless the side where the primary tumor was located, since
the possibility of metastasis at this site must be taken into account.
We did not observe local or systemic recurrence with the reported technique
after a mean follow-up of 18 months.
Using the unilateral dissection below the
inferior mesenteric artery (modified lymphadenectomy), approximately 85
to 90% of patients have their ejaculatory function preserved (1-3,6,9,14).
In this small sample, all patients maintained preserved antegrade ejaculation.
This is fundamentally important, since the main age range affected by
testicular neoplasia comprises young adults in active reproductive phase.
In our initial patient sample, we observed surgical and outcome results
very similar to other works in the literature (2,4,6,14).
As previously exposed, the videolaparoscopic
technique that we employed is similar to open surgery. For releasing the
lymphatic tissue, we preferred to use the ultra-sonic scalpel, because
it reduces the risk of thermal damage to the great vessels and adjacent
organs.
Chemotherapy previously to surgery can make
laparoscopic dissection difficult, due to the occurrence of local fibrosis
of the retroperitoneal tissue that becomes closely adhered to vascular
structures, with higher conversion indexes. However, previous ChT per
se do not prevent the resection of post-ChT mass by videolaparoscopic
approach (5,8,10,12). Some works are contrary to resecting the post-chemotherapy
residual mass by videolaparoscopic access (9). Others advocate laparoscopic
surgery for masses measuring up to 5 cm, showing that this is feasible,
with a higher conversion index (5,8,10,12).
Sutherland & Wright reported one case
of resection of a thoracoabdominal mass successfully using thoracoscopy
and hand-assisted laparoscopic access (13).
The manual conversion in cases of emergency
or difficulty for dissection is original and has not been described in
previously published works. We believe that using this maneuver may be
extremely useful, especially when the surgeon is in the learning curve
or when vascular laparoscopic material is not available. Greater skills
and technical ability with vascular sutures by laparoscopic approach make
this maneuver unnecessary. Even when using a 6- to 7-mm incision, including
the orifice of one of the ports, it is possible to preserve the postoperative
benefits of a minimally invasive surgery (13).
There are few works reporting the results
of long-term oncologic control (19). Additionally, in series of laparoscopic
surgery, patients presenting positive lymph nodes systematically receive
adjuvant chemotherapy, thus it is not possible to assess surgical results
separately. Anyway, the oncologic control seems to be similar to the open
technique (2-12,19).
CONCLUSIONS
Videolaparoscopic
retroperitoneal lymphadenectomy is a procedure with high technical complexity
and a higher potential for emergency conversion when performed after chemotherapy.
In the absence of laparoscopic vascular material, a manual incision can
be sufficient to avoid conversion, maintaining the advantages of the minimally
invasive surgery.
We believe that this method is feasible
for diagnosing and treating stage I and IIa non-seminomatous tumors, or
when the postchemotherapy residual mass is smaller than 6 cm.
REFERENCES
- Richie JP, Steele GS: Neoplasm of the Testis. In: Walsh PC, Retik
AB, Vaughan ED, Wein JA (eds). Campbell’s Urology, ed. 8. Philadelphia,
WB Saunders. 2002; pp. 2876-919.
- Giusti G, Beltrami P, Tallarigo C, Bianchi G, Mobilio G: Unilateral
laparoscopic retroperitoneal lymphadenectomy for clinical stage I non-seminomatous
testicular cancer. J Endourol. 1998; 12: 561-6.
- Janetschek G, Hobisch A, Peschel R, Hittmair A, Bartsch G: Laparoscopic
retroperitoneal lymph node dissection for clinical stage I non-seminomatous
testicular carcinoma: long-term outcome. J Urol. 2000; 163: 1793-6.
- Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P: Long-term experience
with laparoscopic retroperitoneal lymph node dissection in the management
of low-stage testis cancer. Eur Urol. 2000; 37: 251-60.
- Janetschek G, Hobisch A, Hittmnair A, Holti L, Peschel R, Bartsch
G: Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for
stage II B non-seminomatous testicular carcinoma. J Urol. 1999; 161:
477-81.
- Janetschek G: Laparoscopic retroperitoneal lymph node dissection.
In Sakti Das (ed). The Urologic Clinics of North America-Advanced Urologic
Laparoscopy. Philadelphia, WB Saunders. 2001; 28: 107-14.
- Janetschek G, Hobisch A, Holtl L, Bartsch G: Retroperitoneal lymphadenectomy
for clinical stage I nonseminomtous testicular tumor: laparoscopy versus
open surgery and impact of learning curve. J Urol. 1996; 156: 89-93.
- Mariano MB, Tefilli MV: Laparoscopy retroperitoneal lymphadenectomy
after chemotherapy for stage II B testicular tumors. Int Braz J Urol.
2001; 27: 527-34.
- Rassweiler JJ, Seemann O, Henkel TO, Stock C, Frede T, Alken P: Laparoscopic
retroperitoneal lymph node dissection for non-seminomatous germ cell
tumor: indications and limitations. J Urol. 1996; 156: 1108-13.
- Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan
LD: Retroperitoneal lymphadenectomy for post-chemotherapy residual masses:
is a modified dissection and resection of residual masses sufficient?
Br J Urol. 1998; 81: 295-99.
- Wood DP Jr, Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, et
al.: Distribution of retroperitoneal metastasis after chemotherapy in
patients with non-seminomatous germ cell tumors. J Urol. 1992; 148:
1812-15.
- Gelderman WA, Koops HS, Sleijfer DT, Oosterhuis JW, Oldhoff J: Treatment
of retroperitoneal residual tumor after PVB chemotherapy of non-seminomatous
testicular tumors. Cancer.1986; 58: 1418-21.
- Sutherland A, Wright G: Hand-assisted laparoscopic lymphadenectomy:
a novel approach to a difficult area. ANZ J Surg. 2003; 73: 755-7.
- Janetschek G: Laparoscopic retroperitoneal lymph node dissection.
Urol Clin North Am. 2001; 28: 107-14.
- Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R: Retroperitoneal
lymphadenectomy for clinical stage A non-seminomatous germ cell testis
cancer: Review of the Indiana University experience 1965-1989. Br J
Urol. 1993: 71: 326-35.
- Atsu N, Eskicorapci S, Uner A, Ekici S, Gungen Y, Erkan I, et al.:
A novel surveillance protocol for stage I non-seminomatous germ cell
testicular tumors. BJU Int. 2003; 92: 32-5.
- Hoskin P, Dilly S, Easton D, Horwich A, Hendry W, Peckham MJ: Prognostic
factors in stage I non-seminomatous germ-cell testicular tumors managed
by orchiectomy and surveillance: Implications for adjuvant chemotherapy.
J Clin Oncol. 1986; 4: 1031-6.
- Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE: Long-term results
following adjuvant chemotherapy in patients with clinical stage I testicular
non-seminomatous malignant germ cell tumors with high risk factors.
J Urol. 1999; 161: 1148-52.
- Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR: Laparoscopic retroperitoneal
lymph node dissection for clinical stage I nonseminimatous germ cell
testicular cancer: a long- term update. Urology. 2003; 62: 324-7.
_________________________
Received: December 23, 2003
Accepted after revision: September 11, 2004
_______________________
Correspondence
address:
Dr. Marcos Tobias-Machado
Rua Graúna 104 / 131
São Paulo, SP, 04514-000, Brazil
Fax: + 55 11 288-1003
E-mail: tobias-machado@uol.com.br
EDITORIAL
COMMENT
The
authors describe their initial experience with transperitoneal laparoscopic
retroperitoneal lymphadenectomy in a group of 7 patients with non-seminomatous
testicular tumors. Five patients presented clinical stage I, and 2 patients
had postchemotherapy residual masses.
Testicular cancer, though relatively rare,
is the most common tumor in men aged between 15 and 35 years. It also
represents the solid neoplasia with higher possibility of cure, serving
as an example of an almost perfect therapeutic synergism between the different
oncologic expertise fields. The dramatic improvement in survival of this
population results from the combination of more accurate diagnostic techniques,
availability of tumor markers, effective chemotherapy schemes and modifications
in surgical techniques, which, jointly, reduced the mortality from 60%
in the 70s to less than 10% in mid-90s. Thus, with the availability of
effective therapeutic options, even for patients with advanced disease,
efforts have been focused to reducing the morbidity, with potential improvements
in the current protocols.
In this setting, videolaparoscopic surgery
seems to be an attractive approach, both for initial staging of non-seminomatous
tumors and for selected cases of patients with postchemotherapy residual
masses.
As the authors emphasize, there is a long-lasting
discussion in urologic literature concerning the best approach to stage
I non-seminomatous tumors. While some advocate a careful follow-up, based
on the efficacy of chemotherapic agents, others prefer the retroperitoneal
lymphadenectomy with diagnostic and therapeutic purposes, stressing the
fact that microscopic metastases can coexist in up to 30% of cases. The
laparoscopic retroperitoneal lymphadenectomy appears to provide an optimal
alternative in such cases, being a procedure with low morbidity that is
routinely used, which allows us to be more liberal when indicating lymphadenectomy
in these cases, with better acceptance by patients and clinical oncologists,
thus avoiding the anxiety involved in long and consuming observation protocols.
An equally polemic discussion concerns the
recommendation of lymphadenectomy in postchemotherapy residual masses.
Advanced testicular neoplasias are better managed by a combination of
chemotherapy and surgery, conceptually including primary chemotherapy
followed by retroperitoneal lymphadenectomy for residual masses. In order
to reduce the procedural morbidity, we have replaced open classic lymphadenectomy
for the laparoscopic approach in selected cases, as it seems to be the
tendency of this manuscript’s authors. Despite being technically
feasible following chemotherapy, we indicate this procedure only to single
and/or unilateral multiple residual masses measuring no more than 5 cm.
Postchemotherapy laparoscopic retroperitoneal lymphadenectomy is a technically
complex procedure with some potentially serious complications, and to
the moment it must not be encouraged outside services with a large experience
in laparoscopic retroperitoneal surgery.
Dr.
Mirandolino B. Mariano
Dr. Marcos V. Tefelli
Urology Division
Mãe de Deus Hospital
Porto Alegre, RS, Brazil |